Cardiorenal Disease in COVID-19 Patients

Area of Science:

• Cardiology
• Nephrology
• Infectious Diseases

Background:

• Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, presents varied severity.
• Comorbidities such as diabetes, hypertension, and renal disease are linked to severe COVID-19 outcomes and mortality.
• The angiotensin-converting enzyme 2 (ACE2) receptor is the primary entry point for SARS-CoV-2 into human cells.

Purpose of the Study:

• To review the association between cardiorenal disease and COVID-19.
• To discuss the management strategies for patients with both conditions.

Main Methods:

• Literature review of existing studies on COVID-19, cardiorenal disease, and ACE2.
• Analysis of the role of genetic mutations, spike proteins, and comorbidities in disease progression.

Main Results:

• Mutations and spike protein variations influence viral fusion and disease severity.
• Comorbidities, particularly metabolic syndrome components, are associated with increased COVID-19 morbidity.
• Endothelial dysfunction and increased ACE2 expression are critical in COVID-19 complications.

Conclusions:

• Cardiorenal disease significantly impacts COVID-19 severity and mortality.
• Understanding the interplay between ACE2, endothelial function, and comorbidities is crucial for managing COVID-19 patients.